Fig. 1From: The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831CONSORT diagram. *Reasons for clinical ineligibility: failed central and reference laboratory review for HER2 positivity (193), patient cancelled (22), patient lost to follow-up (96), and other reasons for clinical ineligibility (42), where the numbers are combined for Arms A and C. Note that Arm A includes 148 otherwise eligible patients who were enrolled during the Arm C closureBack to article page